Evogene Past Earnings Performance
Past criteria checks 0/6
Evogene's earnings have been declining at an average annual rate of -6.8%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 30.7% per year.
Key information
-6.8%
Earnings growth rate
6.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 30.7% |
Return on equity | -90.5% |
Net Margin | -423.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rots
Oct 12Evogene unit launches 2nd-gen medical cannabis products in Israel
Sep 21Lavie Bio appoints Guri Oron as CEO
Sep 14Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33M
Aug 31Evogene regains compliance with Nasdaq's minimum bid price requirement
Aug 25Evogen stock rises after unit gets $10M investment from ICL under collaboration agreement
Aug 17Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus
Mar 22Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)
Mar 03Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market
Sep 14Evogene: Bullish With Canonic's Entry Into Israeli Medical Cannabis Markets
Jun 16Evogene EPS beats by $0.01, beats on revenue
May 26Evogene unit - Canonic inks cultivation deal for medical cannabis varieties
Dec 23AgPlenus reaches a 'Lead' Stage in its mode-of-action herbicide program
Dec 15Evogene: Q3 Update And Upcoming Catalysts
Nov 30Revenue & Expenses BreakdownBeta
How Evogene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 6 | -24 | 10 | 21 |
30 Sep 23 | 6 | -20 | 10 | 20 |
30 Jun 23 | 2 | -23 | 10 | 20 |
31 Mar 23 | 2 | -25 | 10 | 20 |
31 Dec 22 | 2 | -27 | 10 | 21 |
30 Sep 22 | 1 | -31 | 10 | 22 |
30 Jun 22 | 1 | -32 | 11 | 23 |
31 Mar 22 | 1 | -29 | 10 | 22 |
31 Dec 21 | 1 | -28 | 10 | 21 |
30 Sep 21 | 1 | -29 | 10 | 20 |
30 Jun 21 | 1 | -26 | 9 | 18 |
31 Mar 21 | 1 | -24 | 8 | 17 |
31 Dec 20 | 1 | -23 | 8 | 17 |
30 Sep 20 | 1 | -21 | 7 | 18 |
30 Jun 20 | 1 | -21 | 7 | 17 |
31 Mar 20 | 0 | -21 | 7 | 17 |
31 Dec 19 | 1 | -18 | 6 | 16 |
30 Sep 19 | 1 | -18 | 5 | 14 |
30 Jun 19 | 2 | -18 | 5 | 15 |
31 Mar 19 | 2 | -19 | 5 | 15 |
31 Dec 18 | 2 | -21 | 6 | 15 |
30 Sep 18 | 2 | -21 | 6 | 15 |
30 Jun 18 | 2 | -21 | 6 | 16 |
31 Mar 18 | 3 | -21 | 6 | 16 |
31 Dec 17 | 3 | -21 | 5 | 17 |
30 Sep 17 | 4 | -21 | 6 | 17 |
30 Jun 17 | 5 | -21 | 5 | 17 |
31 Mar 17 | 5 | -21 | 6 | 17 |
31 Dec 16 | 7 | -20 | 6 | 16 |
30 Sep 16 | 8 | -18 | 6 | 16 |
30 Jun 16 | 9 | -17 | 6 | 15 |
31 Mar 16 | 10 | -17 | 6 | 15 |
31 Dec 15 | 11 | -17 | 6 | 14 |
30 Sep 15 | 12 | -17 | 6 | 15 |
30 Jun 15 | 12 | -17 | 6 | 15 |
31 Mar 15 | 13 | -16 | 6 | 15 |
31 Dec 14 | 15 | -15 | 6 | 14 |
30 Sep 14 | 17 | -14 | 6 | 13 |
30 Jun 14 | 18 | -12 | 6 | 12 |
31 Mar 14 | 18 | -11 | 5 | 12 |
31 Dec 13 | 15 | -9 | 5 | 11 |
30 Sep 13 | 18 | -5 | 4 | 10 |
30 Jun 13 | 18 | -4 | 4 | 9 |
Quality Earnings: EVGN is currently unprofitable.
Growing Profit Margin: EVGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EVGN is unprofitable, and losses have increased over the past 5 years at a rate of 6.8% per year.
Accelerating Growth: Unable to compare EVGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EVGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: EVGN has a negative Return on Equity (-90.48%), as it is currently unprofitable.